Development of peptides specifically modulating the activity of KLK2 and KLK3

Biological Chemistry

Volumn 389, Issue 6, 2008, Pages 633-642

  Koistinen, Hannu ^a   Närvänen, Ale ^b   Pakkala, Miikka ^b   Hekim, Can ^a   Mattsson, Johanna M ^a   Zhu, Lei ^a   Laakkonen, Pirjo ^c   Stenman, Ulf Håkan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

hK2; Kallikrein; Peptide modification; Phage display; Prostate cancer; PSA

Indexed keywords

ALANYLARGINYLARGINYLPROLYLALANYLPROLYLALANYLPROLYLGLYCINE; ALANYLARGINYLPHENYLALANYLLYSYLVALYLTRYPTOPHYLTRYPTOPHYLASPARAGINE; ALANYLARGINYLPHENYLALANYLLYSYLVALYLTRYPTOPHYLTRYPTOPHYLGLYCINE; CYSTEINYLALANYLARGINYLARGINYLPROLYLALANYLPROLYLALANYLPROLYLCYSTEINYL GLYCINE; CYSTEINYLVALYLALANYLTYROSYLCYSTEINYLISOLEUCYLGLUTAMYLHISTIDYLHISTIDYL CYSTEINYLTRYPTOPHYLTHREONYLCYSTEINE; CYSTEINYLVALYLPHENYLALANYLALANYLHISTIDYLASPARAGINYLTYROSYLASPARTYL TYROSYLLEUCYLVALYLCYSTEINE; CYSTEINYLVALYLPHENYLALANYLTHREONYLSERYLASPARTYLTYROSYLALANYLPHENYL ALANYLCYSTEINE; GLYCYLALANYLALANYLARGINYLARGINYLPROLYLPHENYLALANYLPROLYLALANYL PROLYLSERYLGLYCINE; GLYCYLCYSTEINYLALANYLALANYLARGINYLPHENYLALANYLLYSYLVALYL TRYPTOPHYLTRYPTOPHYLALANYLCYSTEINYLGLYCINE; KALLIKREIN 2; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; SERYLARGINYLPHENYLALANYLLYSYLPHENYLALANYLVALYLTRYPTOPHYL TRYPTOPHYLALANYLALANYLGLYCINE;

ANGIOGENESIS; CANCER GROWTH; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; METASTASIS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; HUMANS; KALLIKREINS; MALE; PEPTIDES; PROSTATIC NEOPLASMS; SUBSTRATE SPECIFICITY;

EID: 47549092958     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.076     Document Type: Conference Paper

References (108)

1. Abrahamsson, P.A., Lilja, H., Falkmer, S., and Wadstrom, L.B. (1988). Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12, 39-46.
2. Adessi, C. and Soto, C. (2002). Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963-978.
3. Albericio, F. (2004). Developments in peptide and amide synthesis. Curr. Opin. Chem. Biol. 8, 211-221.
4. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
5. Begg, C.B., Riedel, E.R., Bach, P.B., Kattan, M.W., Schrag, D., Warren, J.L., and Scardino, P.T. (2002). Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 346, 1138-1144.
6. Benedetti, E., Morelli, G., Accardo, A., Mansi, R., Tesauro, D., and Aloj, L. (2004). Criteria for the design and biological characterization of radiolabeled peptide-based pharmaceuticals. BioDrugs 18, 279-295.
7. Benuck, M. and Marks, N. (1976). Differences in the degradation of hypothalamic releasing factors by rat and human serum. Life Sci. 19, 1271-1276.
8. Boerman, O.C., Oyen, W.J., and Corstens, F.H. (2000). Radiolabeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med. 30, 195-208.
9. Borgoño, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
10. Cao, Y. (2001). Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33, 357-369.
11. Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K.M., Coplen, D.E., Yuan, J.J., Petros, J.A., and Andriole, G.L. (1991). Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156-1161.
12. Clark, R.J., Fischer, H., Dempster, L., Daly, N.L., Rosengren, K.J., Nevin, S.T., Meunier, F.A., Adams, D.J., and Craik, D.J. (2005). Engineering stable peptide toxins by means of backbone cyclization: stabilization of the α-conotoxin MII. Proc. Natl. Acad. Sci. USA 102, 13767-13772.
13. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
14. Cloutier, S.M., Chagas, J.R., Mach, J.P., Gygi, C.M., Leisinger, H.J., and Deperthes, D. (2002). Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur. J. Biochem. 269, 2747-2754.
15. Cloutier, S.M., Kundig, C., Felber, L.M., Fattah, O.M., Chagas, J.R., Gygi, C.M., Jichlinski, P., Leisinger, H.J., and Deperthes, D. (2004). Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur. J. Biochem. 271, 607-613.
16. Cohen, P., Graves, H.C., Peehl, D.M., Kamarei, M., Giudice, L.C., and Rosenfeld, R.G. (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75, 1046-1053.
17. Coombs, G.S., Bergstrom, R.C., Pellequer, J.L., Baker, S.I., Navre, M., Smith, M.M., Tainer, J.A., Madison, E.L., and Corey, D.R. (1998). Substrate specificity of prostate-specific antigen (PSA). Chem. Biol. 5, 475-488.
18. Cramer, S.D., Chen, Z., and Peehl, D.M. (1996). Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156, 526-531.
19. Dallas, S.L., Zhao, S., Cramer, S.D., Chen, Z., Peehl, D.M., and Bonewald, L.F. (2005). Preferential production of latent transforming growth factor β-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J. Cell Physiol. 202, 361-370.
20. Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Young, C.Y., Klee, G.G., Tindall, D.J., and Bostwick, D.G. (1997). Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49, 857-862.
21. Davies, J.S. (2003). The cyclization of peptides and depsipeptides. J. Pept. Sci. 9, 471-501.
22. DeFeo-Jones, D., Garsky, V.M., Wong, B.K., Feng, D.M., Bolyar, T., Haskell, K., Kiefer, D.M., Leander, K., McAvoy, E., Lumma, P., et al. (2000). A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. 6, 1248-1252.
23. Denmeade, S.R., Jakobsen, C.M., Janssen, S., Khan, S.R., Garrett, E.S., Lilja, H., Christensen, S.B., and Isaacs, J.T. (2003). Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer Inst. 95, 990-1000.
24. Denmeade, S.R., Sokoll, L.J., Chan, D.W., Khan, S.R., and Isaacs, J.T. (2001). Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48, 1-6.
25. Ferrieu-Weisbuch, C., Michel, S., Collomb-Clerc, E., Pothion, C., Deleage, G., and Jolivet-Reynaud, C. (2006). Characterization of prostate-specific antigen binding peptides selected by phage display technology. J. Mol. Recognit. 19, 10-20.
26. Folkman, J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286.
27. Fonovic, M. and Bogyo, M. (2007). Activity based probes for proteases: applications to biomarker discovery, molecular imaging and drug screening. Curr. Pharm. Des. 13, 253-261.
28. Fortier, A.H., Holaday, J.W., Liang, H., Dey, C., Grella, D.K., Holland-Linn, J., Vu, H., Plum, S.M., and Nelson, B.J. (2003). Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56, 212-219.
29. Fortier, A.H., Nelson, B.J., Grella, D.K., and Holaday, J.W. (1999). Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91, 1635-1640.
30. Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C., Pietras, K., Gústafsdóttir, S.M., Ostman, A., and Landegren, U. (2002). Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 20, 473-477.
31. Frenette, G., Deperthes, D., Tremblay, R.R., Lazure, C., and Dube, J.Y. (1997a). Purification of enzymatically active kallikrein hK2 from human seminal plasma. Biochim. Biophys. Acta 1334, 109-115.
32. Frenette, G., Tremblay, R.R., Lazure, C., and Dube, J.Y. (1997b). Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71, 897-899.
33. Goya, M., Ishii, G., Miyamoto, S., Hasebe, T., Nagai, K., Yonou, H., Hatano, T., Ogawa, Y., and Ochiai, A. (2006). Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 66, 1573-1584.
34. Gullberg, M., Gústafsdóttir, S.M., Schallmeiner, E., Jarvius, J., Bjarnegård, M., Betsholtz, C., Landegren, U., and Fredriksson, S. (2004). Cytokine detection by antibody-based proximity ligation. Proc. Natl. Acad. Sci. USA 101, 8420-8424.
35. Hassan, M.I., Kumar, V., Somvanshi, R.K., Dey, S., Singh, T.P., and Yadav, S. (2007). Structure-guided design of peptidic ligand for human prostate specific antigen. J. Pept. Sci. 13, 849-855.
36. Heidtmann, H.H., Nettelbeck, D.M., Mingels, A., Jager, R., Welker, H.G., and Kontermann, R.E. (1999). Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer 81, 1269-1273.
37. Hekim, C., Leinonen, J., Närvänen, A., Koistinen, H., Zhu, L., Koivunen, E., Väisänen, V., and Stenman, U.H. (2006). Novel peptide inhibitors of human kallikrein 2. J. Biol. Chem. 281, 12555-12560.
38. Herrala, A.M., Porvari, K.S., Kyllönen, A.P., and Vihko, P.T. (2001). Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 92, 2975-2984.
39. Hugo, H., Ackland, M.L., Blick, T., Lawrence, M.G., Clements, J.A., Williams, E.D., and Thompson, E.W. (2007). Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 213, 374-383.
40. 2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett. 207, 79-87.
41. Iwamura, M., Hellman, J., Cockett, A.T., Lilja, H., and Gershagen, S. (1996). Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48, 317-325.
42. Janssen, S., Rosen, D.M., Ricklis, R.M., Dionne, C.A., Lilja, H., Christensen, S.B., Isaacs, J.T., and Denmeade, S.R. (2006). Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 66, 358-368.
43. Killian, C.S., Corral, D.A., Kawinski, E., and Constantine, R.I. (1993). Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 192, 940-947.
44. Koblinski, J.E., Ahram, M., and Sloane, B.F. (2000). Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135.
45. Koistinen, H., Paju, A., Koistinen, R., Finne, P., Lövgren, J., Wu, P., Seppälä, M., and Stenman, U.H. (2002). Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50, 112-118.
46. Koistinen, H., Wohlfahrt, G., Mattson, J.M., Wu, P., Lahdenperä, J., and Stenman, U.H. (2008). Novel small molecule inhibitors for prostate-specific antigen. Prostate, in press.
47. Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkilä, P., Kantor, C., Gahmberg, C.G., Salo, T., Konttinen, Y.T., et al. (1999). Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768-774.
48. Kubota, Y., Kleinman, H.K., Martin, G.R., and Lawley, T.J. (1988). Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 107, 1589-1598.
49. Laakkonen, P., Åkerman, M.E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R.M., and Ruoslahti, E. (2004). Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA 101, 9381-9386.
50. Laakkonen, P., Porkka, K., Hoffman, J.A., and Ruoslahti, E. (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8, 751-755.
51. Ladner, R.C., Sato, A.K., Gorzelany, J., and de Souza, M. (2004). Phage display-derived peptides as therapeutic alternatives to antibodies. Drug. Discov. Today 9, 525-529.
52. Li, P. and Roller, P.P. (2002). Cyclization strategies in peptide derived drug design. Curr. Top. Med. Chem. 2, 325-341.
53. Lilja, H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899-1903.
54. Lopez-Otin, C. and Matrisian, L.M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
55. Lövgren, J., Rajakoski, K., Karp, M., Lundwall, A., and Lilja, H. (1997). Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 238, 549-555.
56. Lundwall, Å., Band, V., Blaber, M., Clements, J.A., Courty, Y., Diamandis, E.P., Fritz, H., Lilja, H., Malm, J., Maltais, L.J., et al. (2006). A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387, 637-641.
57. Mattsson, J.M., Valmu, L., Laakkonen, P., Stenman, U.H., and Koistinen, H. (2008). Structural characterization and antiangiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate in press.
58. Ménez, R., Michel, S., Muller, B.H., Bossus, M., Ducancel, F., Jolivet-Reynaud, C., and Stura, E.A. (2008). Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody. J. Mol. Biol. 376, 1021-1033.
59. Mikolajczyk, S.D., Millar, L.S., Kumar, A., and Saedi, M.S. (1999). Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int. J. Cancer 81, 438-442.
60. Nilsson, O., Andersson, I., Peter, A., and Karlsson, B. (1999). Characterization of antibodies to prostate-specific antigen. Tumor Biol. 20 (Suppl. 1), 43-51.
61. Nixon, A.E. (2002). Phage display as a tool for protease ligand discovery. Curr. Pharm. Biotechnol. 3, 1-12.
62. Nyberg, P., Xie, L., and Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. Cancer. Res. 65, 3967-3979.
63. Okarvi, S.M. (2004). Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev. 24, 357-397.
64. Olsson, A.Y., Bjartell, A., Lilja, H., and Lundwall, A. (2005). Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int. J. Cancer 113, 290-297.
65. Overall, C.M. and Kleifeld, O. (2006). Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239.
66. Paju, A., Bjartell, A., Zhang, W.M., Nordling, S., Borgström, A., Hansson, J., and Stenman, U.H. (2000). Expression and characterization of trypsinogen produced in the human male genital tract. Am. J. Pathol. 157, 2011-2021.
67. Paju, A., Hotakainen, K., Cao, Y., Laurila, T., Gadaleanu, V., Hemminki, A., Stenman, U.H., and Bjartell, A. (2007). Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur. Urol. 52, 1670-1679
68. Pakkala, M., Jylhäsalmi, A., Wu, P., Leinonen, J., Stenman, U.H., Santa, H., Vepsäläinen, J., Peräkylä, M., and Närvänen, A. (2004). Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity. J. Pept. Sci. 10, 439-447.
69. Pakkala, M., Hekim, C., Soininen, P., Leinonen, J., Koistinen, H., Weisell, J., Stenman, U.H., Vepsäläinen, J., and Närvänen, A. (2007). Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. J. Pept. Sci. 13, 348-353.
70. Pampalakis, G. and Sotiropoulou, G. (2007). Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta 1776, 22-31.
71. Papadopoulos, I., Sivridis, E., Giatromanolaki, A., and Koukourakis, M.I. (2001). Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin. Cancer Res. 7, 1533-1538.
72. Papatsoris, A.G., Karamouzis, M.V., and Papavassiliou, A.G. (2005). Novel insights into the implication of the IGF-1 network in prostate cancer. Trends. Mol. Med. 11, 52-55.
73. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
74. Pezzato, E., Sartor, L., Dell'Aica, I., Dittadi, R., Gion, M., Belluco, C., Lise, M., and Garbisa, S. (2004). Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int. J. Cancer 112, 787-792.
75. Rehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, F., and Moreau, T. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 268, 2960-2968.
76. Robert, M., Gibbs, B.F., Jacobson, E., and Gagnon, C. (1997). Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 36, 3811-3819.
77. Romanov, V.I., Whyard, T., Adler, H.L., Waltzer, W.C., and Zucker, S. (2004). Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen. Cancer Res. 64, 2083-2089.
78. Samani, A.A., Yakar, S., LeRoith, D., and Brodt, P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47.
79. Sato, A.K., Viswanathan, M., Kent, R.B., and Wood, C.R. (2006). Therapeutic peptides: technological advances driving peptides into development. Curr. Opin. Biotechnol. 17, 638-642.
80. Schedlich, L.J., Bennetts, B.H., and Morris, B.J. (1987). Primary structure of a human glandular kallikrein gene. DNA 6, 429-437.
81. Sergeeva, A., Kolonin, M.G., Molldrem, J.J., Pasqualini, R., and Arap, W. (2006). Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 58, 1622-1654.
82. Shaw, J.L. and Diamandis, E.P. (2007). Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53, 1423-1432.
83. Sloane, B.F., Sameni, M., Podgorski, I., Cavallo-Medved, D., and Moin, K. (2006). Functional imaging of tumor proteolysis. Annu. Rev. Pharmacol. Toxicol. 46, 301-315.
84. Smith, G.P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317.
85. Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., and Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909-916.
86. Stefanidakis, M. and Koivunen, E. (2004). Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr. Pharm. Des. 10, 3033-3044.
87. Stege, R., Grande, M., Carlstrom, K., Tribukait, B., and Pousette, A. (2000). Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. 6, 160-165.
88. Stenman, U.H. (1997). Prostate-specific antigen, clinical use and staging: an overview. Br. J. Urol. 79 (Suppl. 1), 53-60.
89. Stenman, U.H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., and Alfthan, O. (1991). A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51, 222-226.
90. Stenman, U.H., Hakama, M., Knekt, P., Aromaa, A., Teppo, L., and Leinonen, J. (1994). Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344, 1594-1598.
91. Stenman, U.H., Abrahamsson, P.A., Aus, G., Lilja, H., Bangma, C., Hamdy, F.C., Boccon-Gibod, L., and Ekman, P. (2005). Prognostic value of serum markers for prostate cancer. Scand. J. Urol. Nephrol. Suppl. 216, 64-81.
92. Steuber, T., Vickers, A.J., Serio, A.M., Vaisanen, V., Haese, A., Pettersson, K., Eastham, J.A., Scardino, P.T., Huland, H., and Lilja, H. (2007). Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin. Chem. 53, 233-240.
93. Sutkowski, D.M., Goode, R.L., Baniel, J., Teater, C., Cohen, P., McNulty, A.M., Hsiung, H.M., Becker, G.W., and Neubauer, B.L. (1999). Growth regulation of prostatic stromal cells by prostate-specific antigen. J. Natl. Cancer Inst. 91, 1663-1669.
94. Takayama, T.K., Fujikawa, K., and Davie, E.W. (1997). Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272, 21582-21588.
95. Torchilin, V.P. and Lukyanov, A.N. (2003). Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug. Discov. Today 8, 259-266.
96. Turk, B. (2006). Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799.
97. Veveris-Lowe, T.L., Lawrence, M.G., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L., and Clements, J.A. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat. Cancer 12, 631-643.
98. Webber, M.M., Waghray, A., and Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089-1094.
99. Weiner, R.E. and Thakur, M.L. (2005). Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 19, 145-163.
100. Williams, S.A., Merchant, R.F., Garrett-Mayer, E., Isaacs, J.T., Buckley, J.T., and Denmeade, S.R. (2007a). A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J. Natl. Cancer Inst. 99, 376-385.
101. Williams, S.A., Singh, P., Isaacs, J.T., and Denmeade, S.R. (2007b). Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67, 312-329.
102. Wu, P., Leinonen, J., Koivunen, E., Lankinen, H., and Stenman, U.H. (2000). Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem. 267, 6212-6220.
103. Wu, P., Stenman, U.H., Pakkala, M., Närvänen, A., and Leinonen, J. (2004a). Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 58, 345-353.
104. Wu, P., Zhu, L., Stenman, U.H., and Leinonen, J. (2004b). Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin. Chem. 50, 125-129.
105. Wu, P., Koistinen, H., Finne, P., Zhang, W.M., Zhu, L., Leinonen, J., and Stenman, U.H. (2006). Advances in prostate-specific antigen testing. In: Advances in Clinical Chemistry, G. Makowski, ed. (London, UK: Academic Press), pp. 231-261.
106. Yonou, H., Horiguchi, Y., Ohno, Y., Namiki, K., Yoshioka, K., Ohori, M., Hatano, T., and Tachibana, M. (2007). Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-κB ligand expression by human osteoblasts. Prostate 67, 840-848.
107. Yousef, G.M. and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204.
108. Zhu, L., Koistinen, H., Wu, P., Närvänen, A., Schallmeiner, E., Fredriksson, S., Landegren, U., and Stenman, U.H. (2006). A sensitive proximity ligation assay for active PSA. Biol. Chem. 387, 769-772.